Stock Analysis

Incyte Corporation (NASDAQ:INCY) reported Q3 2026 total revenue of $1.56 billion, an increase of 14% compared to the third quarter of 2025. Total net product sales were $1.32 billion, also up 14% year over year, as growth across Opzelura and the Hematology and Oncology …

Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), the Richmond, Virginia-based biopharmaceutical company focused on opioid use disorder treatment, reported its highest-ever quarterly net income and adjusted EBITDA in the third quarter of 2026. Net income reached $137 million, or $1.12 per diluted share, compared with $42 million, …

Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company, reported total revenues of $524.4 million for the third quarter of 2026, a period defined by accelerating commercial momentum behind BRINSUPRI — its treatment for non-cystic fibrosis bronchiectasis — and continued growth from the established ARIKAYCE franchise. …

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), the company behind the FDA-approved TIL therapy lifileucel, presented updated efficacy data from its IOV-LUN-202 Phase 2 trial along with a refined precision development strategy for non-squamous metastatic non-small-cell lung cancer at a medical conference in October 2026. The data, …

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company developing oral small molecule degrader medicines for immunological diseases, reported third-quarter 2026 financial results alongside a significant pipeline milestone: positive Phase 1 healthy volunteer data for KT-579, its investigational IRF5 degrader. The data, which the company …

Laureate Education, Inc. (NASDAQ:LAUR), which operates one of the largest networks of private higher education institutions across Latin America, reported third-quarter 2026 financial results reflecting continued enrollment momentum and improving unitEconomicsacross its markets. The company's performance was shaped by the academic calendar structure in …

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted third quarter 2026 royalty revenue of $70.3 million, a 51% increase from $46.6 million reported in the same period of 2025. The jump was driven by newly acquired XOMA portfolioAssetsalongside continued commercial traction from key royalty partners, including Travere …